Pure Global AI
NCT05661825Recruiting

Cardiac Rehabilitation for the Patients With Acute Myocardial Infarction

The Efficacy and Related Factors in Phase II Cardiac Rehabilitation for the Patients With Acute Myocardial Infarction
Taipei Medical University WanFang HospitalClinicalTrials.govother
Verified
Study focus
Disease/Condition
Acute Myocardial Infarction
Drug/Device/Intervention
phase II cardiac rehabilitation
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Taipei Medical University WanFang Hospital
Location
Taipei, Taiwan
Timeline & enrollment
Phase
N/A
Start date
Feb 01, 2023
End date
Oct 30, 2023
Enrollment
500 participants
Primary outcome

Changes of maximal oxygen consumption after intervention

Summary

The benefits of cardiac rehabilitation include improving exercise tolerance and quality of
 life. However the attending rate of the patients with acute myocardial infarction was low
 according to the previous studies. This is a retrospective chart review study collecting the
 basic characteristics of the patients diagnosed with acute myocardial infarction of Wang-Fang
 Hospital (from Jan 1, 2012 to June 30, 2021). The aims of the studies are to investigate the
 related issues of cardiac rehabilitation including (1) attending rate (2) the efficacy of
 exercise training (3) the factors that limit the participation of the training programs.

ICD-10 classifications
Acute myocardial infarctionAcute myocardial infarction, unspecifiedAcute subendocardial myocardial infarctionCertain current complications following acute myocardial infarctionOther current complications following acute myocardial infarction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05661825
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05661825 through Pure Global AI's free database. This phase not specified trial is sponsored by Taipei Medical University WanFang Hospital and is currently Recruiting. The study focuses on Acute Myocardial Infarction. Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.